1. Home
  2. EVT vs GLPG Comparison

EVT vs GLPG Comparison

Compare EVT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EVT

Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

N/A

Current Price

$26.20

Market Cap

2.0B

Sector

Finance

ML Signal

N/A

Logo Galapagos NV

GLPG

Galapagos NV

N/A

Current Price

$35.84

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVT
GLPG
Founded
N/A
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
EVT
GLPG
Price
$26.20
$35.84
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$36.00
AVG Volume (30 Days)
108.3K
71.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.73
Revenue Next Year
N/A
$0.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.56
$22.59
52 Week High
$26.65
$37.78

Technical Indicators

Market Signals
Indicator
EVT
GLPG
Relative Strength Index (RSI) 55.62 63.49
Support Level $24.07 $31.88
Resistance Level $26.65 $37.78
Average True Range (ATR) 0.31 0.66
MACD -0.05 0.03
Stochastic Oscillator 44.58 70.19

Price Performance

Historical Comparison
EVT
GLPG

About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: